Compare ESLT & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESLT | UTHR |
|---|---|---|
| Founded | 1966 | 1996 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.4B | 20.4B |
| IPO Year | 2002 | 1999 |
| Metric | ESLT | UTHR |
|---|---|---|
| Price | $819.48 | $500.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $550.33 | $520.00 |
| AVG Volume (30 Days) | 128.0K | ★ 336.2K |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | ★ 0.33% | N/A |
| EPS Growth | N/A | ★ 13.07 |
| EPS | N/A | ★ 27.86 |
| Revenue | N/A | ★ $1,483,300,000.00 |
| Revenue This Year | $17.91 | $8.56 |
| Revenue Next Year | $9.55 | $10.71 |
| P/E Ratio | $71.88 | ★ $18.48 |
| Revenue Growth | N/A | ★ 2.38 |
| 52 Week Low | $343.00 | $266.98 |
| 52 Week High | $833.25 | $537.19 |
| Indicator | ESLT | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 75.25 | 54.45 |
| Support Level | $436.67 | $463.64 |
| Resistance Level | N/A | $516.36 |
| Average True Range (ATR) | 25.41 | 18.43 |
| MACD | 9.88 | 3.39 |
| Stochastic Oscillator | 93.17 | 47.44 |
Elbit Systems Ltd is a technology company involved in producing a portfolio of systems and products for aircraft, land, and naval applications. The company's products are used for defense, homeland security, and commercial flight capabilities. Its systems and solutions may be installed on new platforms, or it may perform a comprehensive modernization program to transform a platform. Elbit Systems gives instructions to its customers on the proper maintenance of its products and will provide support team specialists when the customer cannot fix a problem. The company markets its systems and products as a prime contractor or as a subcontractor to government, defense, and homeland security contractors world wide.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.